Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Celleron Therapeutics Ltd.
DescriptionCompound that selectively targets cancer cells through reinstated E2F checkpoint pathway
Molecular Target Undisclosed
Mechanism of ActionE2F activator
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat metastatic cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today